Explore MK-2866 dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator data.
MK-2866 (ostarine) is the most-studied SARM in human trials — a small molecule, not a peptide — sourced in research for muscle-wasting work. It is sold as a research chemical (capsules or an oral liquid), not an approved drug.
Enobosarm binds the androgen receptor as a tissue-selective agonist favouring muscle and bone, with reduced agonist activity at prostate and seminal vesicle relative to testosterone.[5] In the AR+/ER+ metastatic breast cancer indication, enobosarm acts as an agonist of the androgen receptor over-expressed in roughly 80% of ER+ breast tumours — using AR signalling to oppose ER-driven proliferation, a different mechanism than the anabolic premise behind the muscle-wasting program.[2]
The POWER 1 and POWER 2 Phase 3 trials in advanced non-small-cell lung cancer cachexia (Dobs et al., Lancet Oncol 2013) showed lean body mass gains at 3mg/day vs placebo but a mixed signal on physical-function endpoints; the FDA did not grant approval, and GTx discontinued the cachexia program.[1] A Phase 2 in stress urinary incontinence in postmenopausal women showed efficacy on the 24-hour pad-weight endpoint but did not advance. Veru has since pivoted enobosarm into AR+/ER+ metastatic breast cancer — an ARTEST Phase 3 (NCT05572255) is ongoing testing enobosarm plus abemaciclib vs exemestane plus abemaciclib.[2] Case reports of consumer-grade ostarine drug-induced liver injury (DILI) have been published, mirroring the broader SARM-class hepatotoxicity signal.[6]
Not FDA-approved. Veru ARTEST Phase 3 in AR+/ER+ metastatic breast cancer ongoing. FDA warning letters against consumer marketing of ostarine. WADA-prohibited at all times. Research-grade material only.
MK-2866 has a reported half-life of ~24 hours. The pharmacokinetic reference models an interval of once daily; this is not a measured community cadence or a dosing recommendation. A roughly 24-hour half-life makes once-daily dosing sufficient; ostarine accumulates over a few days to a steady level on a single daily dose. Pharmacokinetic source: Ostarine (enobosarm / GTx-024) clinical pharmacokinetic data. It is catalogued under Other Peptides on WPA.
The WPA community has not yet logged enough MK-2866 calculator sessions to publish dose, vial size, or bacteriostatic water distributions for it. This page therefore covers what is known about the compound itself; the usage charts fill in as researchers run the calculator.
These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.